<unk>  (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21.<unk>  targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells.<unk>  was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to<unk>  and are now taking it through late stage clinical testing.
MDX-1097
McN5652
MRK-016
GRAd-COV2
Rc-o319
COVAX-19
ZF2001
BGR-34